COMPANY PROFILE

Amadix

Explore full profile

Non-invasive liquid biopsy tests for early cancer detection

Valladolid, SpainFounded 2010Biotech & Life Sciences

Valuation $5–10M Last recorded · 2020

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amadix

Amadix is a molecular diagnostics company founded in 2010, specializing in the development of non-invasive diagnostic tests for early cancer detection in blood. The company's mission is to extend people's lives by creating disruptive technologies that can identify tumors years before symptoms appear. The firm is headquartered in Valladolid, Spain.

Read full description

The company was founded by Rocío Arroyo, who serves as the CEO. Arroyo has an extensive background in the biopharmaceutical and medical device industries, with previous roles at Eli Lilly and Bionostra Biotechnology Applications. Her experience spans from research and development to business development and strategic management. She is also the President of the Spanish Biotech Companies Association (AseBio).

Amadix's core business revolves around its liquid biopsy technology. The company develops and commercializes diagnostic tests for colon, lung, and pancreatic cancers. Its flagship product, PreveCol®, is a blood-based test for the early detection of colorectal cancer and advanced adenomas (precancerous lesions). PreveCol® uses an algorithm that combines biomarker analysis from a blood sample with a patient's clinical data to provide a result. This test is aimed at individuals aged 50-75 for whom it has been clinically validated. In January 2024, PreveCol® was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), which is intended to expedite the review process for innovative medical devices. The test received its CE marking in May 2022, allowing it to be marketed in the European Union.

The company's business model focuses on the global commercialization of its diagnostic products. By providing a non-invasive alternative to procedures like colonoscopies, Amadix aims to increase patient adherence to screening programs, improve survival rates, and reduce healthcare costs. The company collaborates with international research groups to identify and develop new biomarkers for cancer diagnostics. Its pipeline includes DiagnoLung®, for lung cancer, and PancreaDix®, for pancreatic cancer, both of which are currently under clinical validation.

Amadix has been supported by several venture capital funds, including Inveready, and has received financing from institutions like the European Investment Bank. The company has secured significant funding to scale its operations and expand the commercialization of its tests across Europe and the United States.

Source: Dealroom company data